{"id":"linagliptin-and-basal-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination therapy targets type 2 diabetes through two complementary mechanisms: linagliptin enhances the action of endogenous incretin hormones (GLP-1 and GIP) by blocking their degradation, thereby stimulating insulin secretion in a glucose-dependent manner. Basal insulin provides exogenous long-acting insulin to suppress hepatic glucose production and improve overall glycemic control. Together, they address both postprandial and fasting hyperglycemia.","oneSentence":"Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while basal insulin provides long-acting glucose lowering.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:58.595Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus in patients inadequately controlled on other antidiabetic agents"}]},"trialDetails":[{"nctId":"NCT06946628","phase":"PHASE3","title":"New Triple Therapy in Newly Diagnosed Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Diabetes Mellitus","enrollment":296},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT03429543","phase":"PHASE3","title":"Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-03-20","conditions":"Diabetes Mellitus, Type 2","enrollment":175},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05641337","phase":"PHASE3","title":"Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2022-10-01","conditions":"Liver Cirrhosis, Diabetes","enrollment":184},{"nctId":"NCT04542213","phase":"PHASE3","title":"Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19","status":"COMPLETED","sponsor":"Hospital Regional de Alta Especialidad del Bajio","startDate":"2020-08-01","conditions":"Hyperglycemia, Covid19","enrollment":70},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT03970668","phase":"","title":"Linagliptin in Post-renal Transplantation","status":"COMPLETED","sponsor":"Universidad de Guanajuato","startDate":"2016-01-01","conditions":"Transplanted Kidney Complication","enrollment":28},{"nctId":"NCT02004366","phase":"PHASE4","title":"Linagliptin Inpatient Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":295},{"nctId":"NCT02061969","phase":"PHASE4","title":"ADA Linagliptin in Long Term Care","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-04-25","conditions":"Diabetes","enrollment":140},{"nctId":"NCT02240680","phase":"PHASE4","title":"Linagliptin as Add on to Basal Insulin in the Elderly","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-09-23","conditions":"Diabetes Mellitus, Type 2","enrollment":302},{"nctId":"NCT03051243","phase":"PHASE3","title":"Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2017-10-01","conditions":"DM2","enrollment":60},{"nctId":"NCT00954447","phase":"PHASE3","title":"Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1263}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trajenta (Linagliptin)"],"phase":"phase_3","status":"active","brandName":"Linagliptin and Basal Insulin","genericName":"Linagliptin and Basal Insulin","companyName":"Rabin Medical Center","companyId":"rabin-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while basal insulin provides long-acting glucose lowering. Used for Type 2 diabetes mellitus in patients inadequately controlled on other antidiabetic agents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}